Neoprobe files RIGScan for European Union approval:
This article was originally published in Clinica
Neoprobe has filed its colorectal cancer detection agent, RIGScan, for European approval. Neoprobe, which is based in Dublin, Ohio, has filed dossiers with the European Agency for the Evaluation of Medicinal Products and rapporteur reviewers in Denmark and the UK. An application to the US FDA is planned for late this summer.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.